LungLife AI, Inc. Logo

LungLife AI, Inc.

LLAI.L

(0.8)
Stock Price

8,25 GBp

-108.25% ROA

-45.77% ROE

-0.94x PER

Market Cap.

3.403.617,00 GBp

4.37% DER

0% Yield

-11621.74% NPM

LungLife AI, Inc. Stock Analysis

LungLife AI, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

LungLife AI, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (5%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (2.05x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 ROE

Negative ROE (-45.72%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-82.66%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

LungLife AI, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

LungLife AI, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Buy

LungLife AI, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

LungLife AI, Inc. Revenue
Year Revenue Growth
2018 982.019
2019 136.492 -619.47%
2020 205.180 33.48%
2021 195.566 -4.92%
2022 24.000 -714.86%
2023 46.000 47.83%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

LungLife AI, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 0
2019 0 0%
2020 647.147 100%
2021 1.343.132 51.82%
2022 1.981.000 32.2%
2023 2.616.000 24.27%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

LungLife AI, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 2.837.420
2019 3.096.369 8.36%
2020 3.796.185 18.43%
2021 1.929.893 -96.7%
2022 6.865.000 71.89%
2023 5.474.000 -25.41%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

LungLife AI, Inc. EBITDA
Year EBITDA Growth
2018 -1.926.129
2019 -3.109.759 38.06%
2020 -3.779.183 17.71%
2021 -5.105.015 25.97%
2022 -7.265.000 29.73%
2023 -5.188.000 -40.03%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

LungLife AI, Inc. Gross Profit
Year Gross Profit Growth
2018 908.538
2019 -13.398 6881.15%
2020 17.002 178.8%
2021 99.297 82.88%
2022 24.000 -313.74%
2023 46.000 47.83%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

LungLife AI, Inc. Net Profit
Year Net Profit Growth
2018 -3.249.668
2019 -4.736.125 31.39%
2020 -5.616.209 15.67%
2021 -7.444.188 24.56%
2022 -7.606.000 2.13%
2023 -5.212.000 -45.93%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

LungLife AI, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 0
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

LungLife AI, Inc. Free Cashflow
Year Free Cashflow Growth
2018 -2.142.839
2019 -3.413.877 37.23%
2020 -2.879.353 -18.56%
2021 -9.386.241 69.32%
2022 -5.930.000 -58.28%
2023 -1.196.000 -395.82%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

LungLife AI, Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 -2.142.839
2019 -3.321.963 35.49%
2020 -2.874.025 -15.59%
2021 -7.538.876 61.88%
2022 -5.845.000 -28.98%
2023 -1.160.000 -403.88%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

LungLife AI, Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 0
2019 91.914 100%
2020 5.328 -1625.11%
2021 1.847.365 99.71%
2022 85.000 -2073.37%
2023 36.000 -136.11%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

LungLife AI, Inc. Equity
Year Equity Growth
2018 -3.100.285
2019 -6.797.956 54.39%
2020 19.527.401 134.81%
2021 20.130.096 2.99%
2022 13.140.000 -53.2%
2023 7.913.000 -66.06%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

LungLife AI, Inc. Assets
Year Assets Growth
2018 721.359
2019 1.732.720 58.37%
2020 21.520.901 91.95%
2021 21.966.793 2.03%
2022 15.020.000 -46.25%
2023 9.522.000 -57.74%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

LungLife AI, Inc. Liabilities
Year Liabilities Growth
2018 3.821.644
2019 8.530.676 55.2%
2020 1.993.500 -327.92%
2021 1.836.697 -8.54%
2022 1.880.000 2.3%
2023 1.609.000 -16.84%

LungLife AI, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.16
Price to Earning Ratio
-0.94x
Price To Sales Ratio
98.66x
POCF Ratio
-1.02
PFCF Ratio
-0.91
Price to Book Ratio
0.47
EV to Sales
29.73
EV Over EBITDA
-0.26
EV to Operating CashFlow
-0.28
EV to FreeCashFlow
-0.27
Earnings Yield
-1.07
FreeCashFlow Yield
-1.1
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
1.05
Graham NetNet
0.05

Income Statement Metrics

Net Income per Share
-0.16
Income Quality
0.92
ROE
-0.46
Return On Assets
-0.42
Return On Capital Employed
-0.52
Net Income per EBT
1
EBT Per Ebit
0.96
Ebit per Revenue
-121.09
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
118.28
Research & Developement to Revenue
37.91
Stock Based Compensation to Revenue
3.65
Gross Profit Margin
1
Operating Profit Margin
-121.09
Pretax Profit Margin
-116.06
Net Profit Margin
-116.22

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.14
Free CashFlow per Share
-0.15
Capex to Operating CashFlow
-0.02
Capex to Revenue
2.16
Capex to Depreciation
0.39
Return on Invested Capital
-0.51
Return on Tangible Assets
-1.08
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,11
Book Value per Share
0,31
Tangible Book Value per Share
0.08
Shareholders Equity per Share
0.31
Interest Debt per Share
0.01
Debt to Equity
0.04
Debt to Assets
0.04
Net Debt to EBITDA
0.6
Current Ratio
2.28
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
8063000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.61
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

LungLife AI, Inc. Dividends
Year Dividends Growth

LungLife AI, Inc. Profile

About LungLife AI, Inc.

LungLife AI, Inc., a cancer diagnostics company, develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology. It engages in developing LungLB, an AI enhanced, blood-based test to utilize machine learning to identify and count CTCs with reducing operator hands-on time and increasing test performance. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. The company is based in Thousand Oaks, California.

CEO
Dr. Paul Pagano Ph.D.
Employee
8
Address
2545 West Hillcrest Drive
Thousand Oaks, 91320

LungLife AI, Inc. Executives & BODs

LungLife AI, Inc. Executives & BODs
# Name Age
1 Dr. Paul Pagano Ph.D.
Chief Executive Officer, Chief Scientific Officer & Executive Director
70
2 Mr. David M. Anderson
Chief Financial Officer, Company Secretary & Executive Director
70

LungLife AI, Inc. Competitors

Belluscura plc Logo
Belluscura plc

BELL.L

(0.8)
Verici Dx plc Logo
Verici Dx plc

VRCI.L

(0.8)
Trellus Health plc Logo
Trellus Health plc

TRLS.L

(1.0)
ANGLE plc Logo
ANGLE plc

AGL.L

(1.0)